Heart attack, theatre, stage management, cancer, Yorkshire Terrier, Jesus Christ, Christian, Stage M

Showing posts with label simvastatin. Show all posts
Showing posts with label simvastatin. Show all posts

Sunday, September 15, 2013

Statins Cholestrol protecting properties called into question


     The following is an article I found  from the C.B.C. website via Statin Nation through a post on Facebook


     'Cholestrol-lowering statins are heavily promoted for heart patients but new research is calling into question their use as a preventative medicine.
    Statins such as atorvastatin (Lipitor), rosuvastatin (Crestor) and simvastatin (Zocor) are among the widely used prescription drugs.
    Since the drugs were first marketed 30 years ago in the U.S. for preventing a second heart attack or stroke in those who've already had one, there's been a shift toward prescribing statins for otherwise healthy people in Canada and the U.S.

    "These are patients who really haven't had an event, a cardiovascular event, but they seem to be at high risk," said pharmacy Prof. Muhammad Mamdani, who works at St. Michael's Hospital in Toronto.

    "You also get populations where people seem to be relatively healthy, their cholestrol-lowering aren't that high, but for whatever reason, they are placed on a statin. That's a patient population that is a lot more debatable and some practices may not be warranted."


    More than 38  mllion prescriptions for the class of medications that includes statins were dispensed in Canada last year, according to IMS Brogan. (Kas Roussy/CBC)

    The medical community is debating the pros and cons of using statins for prevention as more independent research comes out on side-effects. This week, a study in JAMA Internal Medicine suggested statins may be associated with an increase in musculoskeletal conditions and pain, especially in physically active individuals. 

    "If you look at all the studies that have ever been done with statins for primary prevention, so for people who have never had a heart attack or a stroke, if you give a statin to a patient for about five years we can reduce the chance of a person having a heart attack or a stroke by about one per cent," said James McCormack, a professor of pharmaceutical sciences at the University of British Columbia. Shifting focus from cholesterol numbers.
    Other potential side-effects include risk of Type 2 diabetes, reversible muscle damage and short-term kidney damage.
    In Canada, as in the U.S., the majority of statin prescriptions go to primary prevention patients, not people with established heart disease, said Dr. Lee Green, a professor and chair of the department of family medicine at the University of Alberta who has surveyed doctors on their prescribing.

    "It seems we need to retrain physicians, and the public, to focus on actual risks, not on a convenient number like cholesterol level," Green said in an email.

    In March, epidemiologist Colin Dormuth, an assistant professor in the department of anesthesiology, pharmacology and therapeutics at the University of British Columbia, looked at the use of high potency statins and rates of admission for acute kidney injury.

    "There are a lot of patients out there taking the drugs right now who don't have a history of heart disease who are hoping to prevent heart disease and in all likelihood will derive absolutely no benefit," Dormuth said.

    In medical circles, discussions continue. A review published in January by British researchers who combed through trials sponsored by drug companies concluded that "statins are likely to be cost-effective in primary prevention."

    People like Jim Matheson, 62, of Toronto, are left to decide with their doctor.

    "Within five years he told me that I had a 20 per cent chance of either having a stroke or a heart attack," Matheson recalled. "He offered me the pill but I didn't want to take it."

    Instead, Matheson opted to eat healthier foods and exercise more. His brother on the other hand decided to go on statins.

    "I have sent him, probably for every article he has sent me on how good they are I have sent him 20 that says how bad they are. We're still having the dialogue," Matheson said.

    "We'll see who lasts longer," he quipped.'

     

    Sunday, January 06, 2013

    Could statins be adding to the epidemic of ‘heart failure’?'

     Doctor  John Briffa writes:

    'Statins are drugs that reduce cholesterol by inhibiting an enzyme in the liver known as ‘HMG-CoA reductase’ which ‘drives’ cholesterol production (most of the cholesterol in the bloodstream is made in the liver and does not come directly from the diet). But HMG-CoA reductase also facilitates the production of a substance known as ‘coenzyme Q10’ which itself participates in the production of what is known as ‘adenosine triphosphate’ (ATP) – the most basic unit of energy ‘fuel’ in the body. The major biochemical process which involves CoQ10 that drives ATP and energy production in the body is known as ‘oxidative phosphorylation’.'

    'Now that we have the potted biochemistry lesson over, we can see that statins have the potential, by lowering CoQ10 levels, to put a break on oxidative phosphorylation and ATP production in the muscles. The end result may be fatigue? Muscle pain is another potential consequence.
    In a study published this week in the Journal of the American College of Cardiology (JACC), Danish researchers measured CoQ10 levels in individuals taking simvastatin (a commonly-prescribed statin), and compared them with those not taking statins [1]. The levels in those taking the statin were significantly lower.'

    'Now, studies such as this one are what is termed ‘epidemiological’ in nature, which means it looks at associations between things, but cannot prove that one thing is causing another. However, of relevance here is other evidence which finds that giving statins to people does indeed have the capacity to lower levels of CoQ10 in the body [2]. '

    'What was also interesting about the JACC study is that it found that those treated with statins had lower levels of oxidative phosphorylation than those not taking them. They also had reduced ‘insulin sensitivity’. This is relevant for a number of reasons, including the fact that insulin facilitates the uptake of nutrients such as glucose into the cells. Lowered insulin sensitivity can therefore ‘starve’ the cells of essential nutrients. Reduced insulin sensitivity is also the underlying fault in type 2 diabetes. It is perhaps worth bearing in mind that statin use has been proven to increase the risk of type 2 diabetes.'

    'Another thing worth bearing in mind here, I think, is the fact that the heart is a muscle, and depleting it of CoQ10 may be hazardous for cardiac health. Specifically, it may weaken the heart and lead to what is known as ‘heart failure’ (also known as ‘congestive cardiac failure’). I think the ‘benefits’ of statins are vastly overstated, generally speaking. However, if someone is to take statins, I think it’s a reasonable safeguard to take CoQ10 on a daily basis. 100 mg a day is a decent dose, I think, though higher doses are likely to better when symptoms of statin toxicity are present.
    In researching this article, I came across an interesting review of the evidence for statin-inducted CoQ10 depletion in both humans and animals [3]. Here’s what the authors of this review have to say in their concluding remarks:
    Statin-induced CoQ10 deficiency is completely preventable with supplemental CoQ10 with no adverse impact on the cholesterol lowering or anti-inflammatory properties of the statin drugs. We are currently in the midst of a congestive heart failure epidemic in the United States, the cause or causes of which are unclear. As physicians, it is our duty to be absolutely certain that we are not inadvertently doing harm to our patients by creating a wide-spread deficiency of a nutrient critically important for normal heart function.'

    The above quoted from drbriffa.com